Creekmur Asset Management LLC Grows Position in Intellia Therapeutics, Inc. $NTLA

Creekmur Asset Management LLC boosted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 43.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 58,600 shares of the company’s stock after purchasing an additional 17,654 shares during the period. Creekmur Asset Management LLC owned approximately 0.06% of Intellia Therapeutics worth $550,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. ARK Investment Management LLC grew its position in Intellia Therapeutics by 3.8% during the 1st quarter. ARK Investment Management LLC now owns 13,011,015 shares of the company’s stock worth $92,508,000 after purchasing an additional 474,629 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Intellia Therapeutics by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company’s stock valued at $76,447,000 after acquiring an additional 561,978 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Intellia Therapeutics by 8.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock valued at $3,709,000 after acquiring an additional 38,521 shares during the last quarter. Jump Financial LLC boosted its holdings in shares of Intellia Therapeutics by 38.9% in the 1st quarter. Jump Financial LLC now owns 503,809 shares of the company’s stock valued at $3,582,000 after acquiring an additional 141,172 shares during the last quarter. Finally, Granahan Investment Management LLC boosted its holdings in shares of Intellia Therapeutics by 55.3% in the 1st quarter. Granahan Investment Management LLC now owns 475,946 shares of the company’s stock valued at $3,384,000 after acquiring an additional 169,436 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Barclays dropped their price objective on shares of Intellia Therapeutics from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday. Chardan Capital dropped their target price on Intellia Therapeutics from $60.00 to $48.00 and set a “buy” rating on the stock in a report on Monday. Citigroup reaffirmed a “market outperform” rating on shares of Intellia Therapeutics in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Wednesday, October 8th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and set a $17.00 target price (down from $45.00) on shares of Intellia Therapeutics in a report on Tuesday. Twelve analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $23.74.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 1,871 shares of the stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the transaction, the chief accounting officer directly owned 55,266 shares of the company’s stock, valued at $960,523.08. This trade represents a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William J. Chase acquired 100,000 shares of the firm’s stock in a transaction on Wednesday, August 20th. The shares were bought at an average cost of $10.03 per share, for a total transaction of $1,003,000.00. Following the completion of the acquisition, the director owned 134,693 shares of the company’s stock, valued at approximately $1,350,970.79. This represents a 288.24% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 3.10% of the company’s stock.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $12.27 on Friday. The company’s fifty day moving average price is $17.08 and its 200 day moving average price is $12.27. Intellia Therapeutics, Inc. has a 1 year low of $5.90 and a 1 year high of $28.25. The company has a market capitalization of $1.32 billion, a PE ratio of -2.62 and a beta of 2.37.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.04. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. The firm had revenue of $14.25 million for the quarter, compared to the consensus estimate of $12.26 million. During the same period in the prior year, the firm posted ($1.52) earnings per share. The firm’s quarterly revenue was up 104.3% compared to the same quarter last year. On average, equities analysts expect that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.